ReviewMicroorganisms2021
Next-Generation Probiotics and Their Metabolites in COVID-19.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Meta-analysis of probiotics metabolites in gastrointestinal tract and metabolic health.Frontiers in cellular and infection microbiology · 2025Pooled it
- Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.Frontiers in cellular and infection microbiology · 2022Pooled it
- Alterations of the gut commensalVirulence · 2025Article
- The dynamic linkage between covid-19 and nutrition: a review from a probiotics perspective using machine learning and bibliometric analysis.Frontiers in nutrition · 2025Article
- Microbial Dynamics in COVID-19: Unraveling the Impact of Human Microbiome on Disease Susceptibility and Therapeutic Strategies.Current microbiology · 2024Review
- Analysis of the Antimicrobial Activity of Epigallocatechin-3-Gallate (EGCG).Bulletin of experimental biology and medicine · 2024Article
- Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives.Microorganisms · 2024Review
- Comparative analysis of oropharyngeal microbiota in healthcare workers post-COVID-19.Frontiers in cellular and infection microbiology · 2024Article
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV.NPJ biofilms and microbiomes · 2023Article
- Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy.International journal of molecular sciences · 2023Review
- The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.Viruses · 2023Review
- Intestinal barrier dysfunction as a key driver of severe COVID-19.World journal of virology · 2023Review
- Can Probiotics, ParticularlyBiology · 2023Review
- Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity.Microorganisms · 2023Review
- Gut microbiota and COVID-19: A systematic review.Health science reports · 2023Article
- Cell-Free Supernatant fromMolecules (Basel, Switzerland) · 2022Article
- Article
- Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show?Clinical nutrition ESPEN · 2022Review
- Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy.World journal of gastroenterology · 2022Review
- Composition of Human Breast Milk Microbiota and Its Role in Children's Health.Pediatric gastroenterology, hepatology & nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since December 2019, a global pandemic has been observed, caused by the emergence of a new coronavirus, SARS CoV-2. The latter is responsible for the respiratory disease, COVID-19. The infection is also characterized by renal, hepatic, and gastrointestinal dysfunctions suggesting the spread of the virus to other organs. A dysregulated immune response was also reported. To date, there is no measure to treat or prevent SARS CoV-2 infection. Additionally, as gut microbiota composition is altered in patients with COVID-19, alternative therapies using probiotics can be considered to fight SARS CoV-2 infection. This review aims at summarizing the current knowledge about next-generation probiotics (NGPs) and their benefits in viral respiratory tract infections and in COVID-19. We describe these bacteria, highlighted by studies using metagenomic approaches. In addition, these bacteria generate metabolites such as butyrate, desaminotyrosine, and secondary bile acid, suggested to prevent viral respiratory infections. Gut microbial metabolites transported via the circulation to the lungs could inhibit viral replication or improve the immune response against viruses. The use of probiotics and/or their metabolites may target either the virus itself and/or the immunologic process. However, this review showed that more studies are needed to determine the benefits of probiotics and metabolite products in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.